Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 1/20 | 0.35 |
| ▸ | BTN3A1 | O00481 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | ENO1 | P06733 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7869641 | 0.88 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL18655571 | 0.85 | TDP1 (0.38) | PRKCABTN3A1ALDH1A1ENO1 | |
| SCHEMBL7715352 | 0.85 | CYP4F2 (0.33) | ALDH1A1CYP4F2CYP4A11 | |
| SCHEMBL681950 | 0.80 | PRKCA (0.46) | PRKCABTN3A1ALDH1A1ENO1POLB | |
| SCHEMBL18655541 | 0.79 | PRKCA (0.33) | PRKCABTN3A1ALDH1A1ENO1 | |
| SCHEMBL2949105 | 0.79 | PRKCA (0.37) | PRKCABTN3A1ALDH1A1ENO1POLB | |
| SCHEMBL391974 | 0.78 | ALDH1A1 (0.33) | ALDH1A1 | |
| Hydrochloric Acid SCHEMBL18757103 | 0.78 | PRKCA (0.32) | PRKCABTN3A1ALDH1A1ENO1 | |
| SCHEMBL6885640 | 0.78 | CYP1A2 (0.36) | ALDH1A1POLBGAACYP4F2CYP4A11 | |
| SCHEMBL1507260 | 0.77 | NAAA (0.39) | ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240190875-A1 | SPIROINDOLINE DERIVATIVE, AND PREPARATION METHOD AND MEDICAL USE THEREOF | CHANGCHUN GENESCIENCE PHARMACEUTICAL CO., LTD. (CN) | 2024-06-13 | — | — | US | disclosed |
| US-11926640-B2 | Prodrugs of glutamine analogs | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-03-12 | — | — | US | disclosed |
| EP-4282867-A1 | INDOLINE-CONTAINING SPIRO DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE | Changchun Genescience Pharmaceutical Co., Ltd. (CN) | 2023-11-29 | — | — | EP | disclosed |
| EP-3328827-B1 | PRODRUGS OF GLUTAMINE ANALOGS | UNIV JOHNS HOPKINS (US) | 2023-07-05 | — | — | EP | disclosed |
| US-20210206787-A1 | PRODRUGS OF GLUTAMINE ANALOGS | Ústav organické chemie a biochemie AV CR, v.v.i. (CZ) | 2021-07-08 | — | — | US | disclosed |
| US-10954257-B2 | Prodrugs of glutamine analogs | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-03-23 | — | — | US | disclosed |
| US-10738066-B2 | Prodrugs of glutamine analogs | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-08-11 | — | — | US | disclosed |
| CN-105801489-B | Cycloalkyl-substituted imidazole derivatives | 第一三共株式会社 | 2019-12-10 | — | — | CN | disclosed |
| US-20190315783-A1 | PRODRUGS OF GLUTAMINE ANALOGS | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), AS COLLATERAL AGENT | 2019-10-17 | — | — | US | disclosed |
| US-20190315784-A1 | PRODRUGS OF GLUTAMINE ANALOGS | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), AS COLLATERAL AGENT | 2019-10-17 | — | — | US | disclosed |
| EP-1668005-B1 | ACYLOXYMETHYLCARBAMATE PRODRUGS OF OXAZOLIDINONES | PHARMACIA & UPJOHN CO LLC (US) | 2007-02-14 | — | — | EP | disclosed |
| US-20060287283-A1 | Prodrugs of 9-aminomethyl tetracycline compounds | PARATEK PHARMACEUTICALS, INC. (US) | 2006-12-21 | — | — | US | disclosed |
| EP-1668005-A1 | ACYLOXYMETHYLCARBAMATE PRODRUGS OF OXAZOLIDINONES | Pharmacia & Upjohn Company LLC (US) | 2006-06-14 | — | — | EP | disclosed |
| EP-1656341-A1 | PRODRUGS OF 9-AMINOMETHYL TETRACYCLINE COMPOUNDS | Paratek Pharmaceuticals, Inc. (US) | 2006-05-17 | — | — | EP | disclosed |
| US-20050267104-A1 | E.g., ({[Acetyl({(5R)-3-[4-(1,1-dioxidotetrahydro-2H-thiopyran4-yl)-3-fluorophenyl]-2-oxo-1,3-oxazolidin-5-yl}-methyl)amino]carbonyl}oxymethyl acetate; these compounds have potent activity with excellent oral bioavailability against Gram-positive and Gram-negative bacteria | PHARMACIA & UPJOHN COMPANY LLC | 2005-12-01 | — | — | US | disclosed |
| US-20050137174-A1 | Prodrugs of 9-aminomethyl tetracycline compounds | PARATEK PHARMACEUTICALS, INC. (US) | 2005-06-23 | — | — | US | disclosed |
| WO-2005028473-A1 | ACYLOXYMETHYLCARBAMATE PRODRUGS OF OXAZOLIDINONES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2005-03-31 | — | — | WO | disclosed |
| WO-2005009944-A1 | PRODRUGS OF 9-AMINOMETHYL TETRACYCLINE COMPOUNDS | PARATEK PHARMACEUTICALS, INC. (US) | 2005-02-03 | — | — | WO | disclosed |
| US-6376548-B1 | FUNGICIDES; HERBICIDES; INSECTICIDES | ROHM AND HAAS COMPANY | 2002-04-23 | — | — | US | disclosed |
| WO-2001056358-A2 | ENHANCED PROPERTIED PESTICIDES | ROHM AND HAAS COMPANY (US) | 2001-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190875-A1 | SPIROINDOLINE DERIVATIVE, AND PREPARATION METHOD AND MEDICAL USE THEREOF | GHSR, GHRHR, NR3C2 | PRKCA 4213/4885BTN3A1 3364/4885ALDH1A1 1759/4885 |
| US-20210206787-A1 | PRODRUGS OF GLUTAMINE ANALOGS | GLUL, GLS, GLS2 | PRKCA 4651/4885BTN3A1 4159/4885ALDH1A1 1032/4885 |
| US-10738066-B2 | Prodrugs of glutamine analogs | GLUL, GLS, GLS2 | PRKCA 4296/4885BTN3A1 3697/4885ALDH1A1 929/4885 |
| US-20050267104-A1 | E.g., ({[Acetyl({(5R)-3-[4-(1,1-dioxidotetrahydro-2H-thiopyran4-yl)-3-fluorophenyl]-2-oxo-1,3-oxazolidin-5-yl}-methyl)amino]carbonyl}oxymethyl acetate; these compounds have potent activity with excellent oral bioavailability against Gram-positive and Gram-negative bacteria | HDAC3, HDAC1, OGA | PRKCA 4355/4885BTN3A1 1029/4885ALDH1A1 591/4885 |
| US-11926640-B2 | Prodrugs of glutamine analogs | GLUL, GLS, GLS2 | PRKCA 4296/4885BTN3A1 3697/4885ALDH1A1 929/4885 |
| US-20190315783-A1 | PRODRUGS OF GLUTAMINE ANALOGS | GLUL, GLS, GLS2 | PRKCA 4296/4885BTN3A1 3697/4885ALDH1A1 929/4885 |
| US-20050137174-A1 | Prodrugs of 9-aminomethyl tetracycline compounds | TET3, TET1, TPMT | PRKCA 4113/4885BTN3A1 3547/4885ALDH1A1 3508/4885 |
| US-20060287283-A1 | Prodrugs of 9-aminomethyl tetracycline compounds | TET3, TET1, TPMT | PRKCA 4113/4885BTN3A1 3547/4885ALDH1A1 3508/4885 |
| US-10954257-B2 | Prodrugs of glutamine analogs | GLUL, GLS, GLS2 | PRKCA 4296/4885BTN3A1 3697/4885ALDH1A1 929/4885 |
| US-20190315784-A1 | PRODRUGS OF GLUTAMINE ANALOGS | GLUL, GLS, GLS2 | PRKCA 4296/4885BTN3A1 3697/4885ALDH1A1 929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.